Chiesi USA,

LAMZEDE

Manufacturer:

Chiesi USA,

Lamzede HCPCS:

J0217

HCPCS Code Descriptor:

Injection, velmanase alfa-tycv, 1 mg

Category:

J Code

Lamzede NDCs:

10122-0180-02

Primary Type:

Enzyme Replacement Therapy

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

10122-0180-01

About Lamzede:

LAMZEDE is a Enzyme Replacement Therapy drug manufactured by Chiesi USA, and administered via the Intravenous route of administration. The J Code: J0217 is aligned to the drug LAMZEDE.

Lamzede is an enzyme replacement therapy used to treat symptoms of alpha-mannosidosis in adults and children. Alpha-mannosidosis is a genetic condition that causes the body to be unable to break down complex sugars. Alpha-mannosidosis is caused by a deficiency of the enzyme alpha-mannosidase. Without alpha-mannosidase, toxic sugars can build up is various organs and tissues in the body.

ACCESS PRICING AND MORE BY REGISTERING

J0217 Added Date:

January 1, 2024

J0217 Effective Date:

January 1, 2024

J0217 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Lamzede billing and coding information.
Lamzede patient assistance information can be found through Chiesi Total Care at the URL: https://chiesitotalcare.com/lamzede/healthcare-professionals/
LAMZEDE prescribing information can be found at the link below:
Information regarding LAMZEDE’s side effects can be found at MedlinePlus